What Next for Celyad SA (CYAD) Stock After Touching 52 Week Low?

May 16, 2018 - By Henry Gaston

Celyad SA (NASDAQ:CYAD) Logo

The stock of Celyad SA (NASDAQ:CYAD) hit a new 52-week low and has $26.12 target or 9.00 % below today’s $28.70 share price. The 8 months bearish chart indicates high risk for the $285.15M company. The 1-year low was reported on May, 16 by Barchart.com. If the $26.12 price target is reached, the company will be worth $25.66M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 6.58% or $2.02 during the last trading session, reaching $28.7. About 3,183 shares traded. Celyad SA (NASDAQ:CYAD) has 0.00% since May 16, 2017 and is . It has underperformed by 11.55% the S&P500.

More notable recent Celyad SA (NASDAQ:CYAD) news were published by: Businesswire.com which released: “Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting” on May 09, 2018, also Nasdaq.com with their article: “Celyad Successfully Administers CYAD-01 in First Patients in SHRINK and LINK Trials” published on May 03, 2018, Benzinga.com published: “26 Stocks Moving In Wednesday’s Pre-Market Session” on May 16, 2018. More interesting news about Celyad SA (NASDAQ:CYAD) were released by: Nasdaq.com and their article: “Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed …” published on April 27, 2018 as well as Seekingalpha.com‘s news article titled: “Celyad -3.3% after announcing 1.8M-unit offering” with publication date: May 15, 2018.

Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell therapies. The company has market cap of $285.15 million. The firm utilizes its expertise in cell engineering to target cancer. It currently has negative earnings. The Company’s CAR-T cell platform has the potential to treats a range of solid and hematologic tumors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: